Corvus Pharmaceuticals (FRA:C17) Net Margin %: 0.00% (As of Mar. 2026)

What is Corvus Pharmaceuticals Net Margin %?

Corvus Pharmaceuticals FRA:C17 +3.41% 32 Net Margin % is 0.00% as of Mar. 2026. GuruFocus rates FRA:C17 with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 946 Biotechnology companies, Corvus Pharmaceuticals ranks worse than 105708.14% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Corvus Pharmaceuticals's Net Income for the three months ended in Mar. 2026 was €-11.84 Mil. Corvus Pharmaceuticals's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, Corvus Pharmaceuticals's net margin for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for Corvus Pharmaceuticals's Net Margin % or its related term are showing as below:

FRA:C17's Net Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -88.815
* Ranked among companies with meaningful Net Margin % only.

Corvus Pharmaceuticals (FRA:C17) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Corvus Pharmaceuticals Net Margin % Related Terms

Corvus Pharmaceuticals Net Margin % Historical Data

* Premium members only.

The historical data trend for Corvus Pharmaceuticals's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corvus Pharmaceuticals Net Margin % Chart

Corvus Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Net Margin %

Get a 7-Day Free Trial

0.00

Corvus Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Net Margin %	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

FRA:C17 vs JBIO, ABSI, SVRA: Net Margin % Comparison

For the Biotechnology subindustry, Corvus Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Corvus Pharmaceuticals Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corvus Pharmaceuticals's Net Margin % distribution charts can be found below:

* The bar in red indicates where Corvus Pharmaceuticals's Net Margin % falls into.

Save Embed

32GF Score

Corvus Pharmaceuticals Inc FRA:C17

Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Corvus Pharmaceuticals Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Corvus Pharmaceuticals's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin	=	Net Income (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-13.052	/	0
	=	%

Corvus Pharmaceuticals's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin	=	Net Income (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-11.844	/	0
	=	%

Frequently Asked Questions Learn more about Net Margin % →

What does a Net Margin % of 0.00% mean?

Corvus Pharmaceuticals (FRA:C17) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Corvus Pharmaceuticals and its competitors. According to the industry distribution chart, Corvus Pharmaceuticals ranks #999999 out of 946 companies in the Biotechnology industry.

Is Corvus Pharmaceuticals' Net Margin % too high?

Corvus Pharmaceuticals' current Net Margin % is 0.00%. Based on the distribution chart, Corvus Pharmaceuticals ranks #999999 out of 946 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Corvus Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.

How does Corvus Pharmaceuticals' Net Margin % compare to JBIO and ABSI?

According to the Biotechnology industry distribution chart, Corvus Pharmaceuticals ranks #999999 out of 946 companies for Net Margin %. This places Corvus Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Net Margin % for a Biotechnology company?

A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Net Margin % mean?

A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Corvus Pharmaceuticals and its competitors. Corvus Pharmaceuticals's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Corvus Pharmaceuticals stock overvalued right now?

Corvus Pharmaceuticals (FRA:C17) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Corvus Pharmaceuticals' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Net Margin % calculated?

Net Margin % is calculated from a company's financial statements. For Corvus Pharmaceuticals (FRA:C17), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corvus Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies JBIO ABSI SVRA CGEM MGTX DRTS LXRX SPTX EYPT AKTS VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges CRVS:USA C17:Germany

Address 901 Gateway Boulevard, Third Floor, South San Francisco, CA, USA, 94080

Website https://www.corvuspharma.com

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

32GF Score

Get the complete analysis for FRA:C17

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.07

Price

View FRA:C17 Analysis

See Net Margin % data for all stocks →